Emergent BioSolutions Inc. (EBS) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 26 PAGES: 48

More Info
									               Emergent BioSolutions Inc. (EBS) - Financial and Strategic SWOT
                                      Analysis Review
        Reference Code: GDPH6940FSA                                                                                           Publication Date: MAR 2013

          2273 Research Boulevard, Suite 400                 Phone              +1 301 7951800                  Revenue          273.4 (million USD)
          Rockville, MD                                      Fax                +1 301 7951899                  Net Profit       23.02 (million USD)
          20850                                              Website            www.ebsi.com                    Employees        811
                                                                                EBS [New York Stock                              Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Emergent BioSolutions Inc. (Emergent) is a biopharmaceutical company. The company operates through two divisions, namely,
       Biodefense and Biosciences. The company’s Biodefense division is directed to government-sponsored development and supply
       of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Emergent’s
       marketed product, BioThrax is the only vaccine approved by the FDA for the prevention of anthrax disease. The Biosciences
       division is directed to commercial opportunities and targets oncology indications.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Emergent BioSolutions Inc., SWOT Analysis
         Fuad El-Hibri                       Chairman                                 Strengths                              Weaknesses
         Daniel J. Abdun-Nabi                Chief Executive Officer
                                                                                      Platform Technologies                  Dependence on Third Parties
         Dr. Sue Bailey                      Director
                                                                                      BioThrax: Growing Market               Dependence on the US
         John E. Niederhuber                 Director
                                                                                      Acceptance                             Government Contracts
         Zsolt Harsanyi, Ph.D.               Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Increasing Awareness for               Cost Containment Pressures
         Emergent BioSolutions Inc.                                                   Vaccines
                                                                                                                             Stringent Government
        Share Price (USD) as on 22-Mar-                                14.37          ‘Fast Track’ Designation               Regulations
        2013
        EPS (USD)                                                        0.64
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         515         GlobalData

        Enterprise Value (million USD)                                   382
        Shares Outstanding (million)                                       36
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 07, 2013         Emergent BioSolutions Reports Revenue Of
                                                                                                           $281.9m In 2012
                                                                                      Nov 19, 2012         Emergent BioSolutions Names Robert Kramer
                                                                                                           As CFO
                                                                                      Nov 01, 2012         Emergent BioSolutions Announces Growth
                                                                                                           Plan Through 2015
                                                                                      Nov 01, 2012         Emergent BioSolutions Reports Revenue Of
                                                                                                           $66.6m In Q3 2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Emergent BioSolutions Inc. (EBS) - Financial and Strategic SWOT                                                                 Reference Code: GDPH6940FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Emergent BioSolutions Inc. - Key Facts ............................................................................................................................................. 5
       Emergent BioSolutions Inc. - Key Employees .................................................................................................................................... 6
       Emergent BioSolutions Inc. - Key Employee Biographies .................................................................................................................. 7
       Emergent BioSolutions Inc. - Major Products and Services ............................................................................................................... 9
       Emergent BioSolutions Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 10
          Emergent BioSolutions Inc., Pipeline Products by Therapy Area ................................................................................................. 10
          Emergent BioSolutions Inc., Pipeline Products by Development Phase ....................................................................................... 11
       Emergent BioSolutions Inc. - History ................................................................................................................................................ 15
       Emergent BioSolutions Inc. - Company Statement .......................................................................................................................... 18
       Emergent BioSolutions Inc. - Locations And Subsidiaries ................................................................................................................ 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 22
       Emergent BioSolutions Inc. - Business Description .......................................................................................................................... 22
       Emergent BioSolutions Inc. - Corporate Strategy ............................................................................................................................. 23
       Emergent BioSolutions Inc. - SWOT Analysis .................................................................................................................................. 24
          SWOT Analysis - Overview........................................................................................................................................................... 24
          Emergent BioSolutions Inc. - Strengths ........................................................................................................................................ 24
             Strength - Platform Technologies .............................................................................................................................................. 24
             Strength - BioThrax: Growing Market Acceptance .................................................................................................................... 24
             Strength - Strong In-House Research Activities ........................................................................................................................ 24
          Emergent BioSolutions Inc. - Weaknesses ................................................................................................................................... 24
             Weakness - Dependence on Third Parties ................................................................................................................................ 24
             Weakness - Dependence on the US Government Contracts .................................................................................................... 25
          Emergent BioSolutions Inc. - Opportunities .................................................................................................................................. 25
             Opportunity - Increasing Awareness for Vaccines ..................................................................................................................... 25
             Opportunity - ‘Fast Track’ Designation ...................................................................................................................................... 25
             Opportunity - Orphan Drug Designation .................................................................................................................................... 25
             Opportunity - Growth Initiatives ................................................................................................................................................. 25
          Emergent BioSolutions Inc. - Threats ........................................................................................................................................... 26
             Threat - Cost Containment Pressures ....................................................................................................................................... 26
             Threat - Stringent Government Regulations .............................................................................................................................. 26
             Threat - Increasing Competitive Pressures ............................................................................................................................... 26
       Emergent BioSolutions Inc. - Key Competitors................................................................................................................................. 27
       Section 3 – Company Financial Ratios ............................................................................................................................................. 28
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 28
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 28
       Performance Chart ........................................................................................................................................................................... 30
       Financial Performance...................................................................................................................................................................... 30
       Financial Ratios - Interim Ratios....................................................................................................................................................... 31
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 32


Emergent BioSolutions Inc. (EBS) - Financial and Strategic SWOT                                                                                                  Reference Code: GDPH6940FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 33
          Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ................................................. 33
          Emergent BioSolutions Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ................................................ 34
       Emergent BioSolutions Inc., Recent Deals Summary ...................................................................................................................... 35
       Section 5 – Company’s Recent Developments ................................................................................................................................ 36
          Emergent BioSolutions Inc., Recent Developments ..................................................................................................................... 36
             Mar 07, 2013: Emergent BioSolutions Reports Revenue Of $281.9m In 2012 ......................................................................... 36
             Nov 19, 2012: Emergent BioSolutions Names Robert Kramer As CFO .................................................................................... 37
             Nov 01, 2012: Emergent BioSolutions Announces Growth Plan Through 2015 ........................................................................ 37
             Nov 01, 2012: Emergent BioSolutions Reports Revenue Of $66.6m In Q3 2012 ..................................................................... 38
             Oct 11, 2012: Emergent BioSolutions Selects Qumas Compliance Platform To Manage Quality A
								
To top